导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.81% | 1810/4773 |
| 近一周 | -3.32% | 4053/5462 |
| 近一月 | -10.42% | 5068/5421 |
| 近一季 | -19.42% | 4830/5209 |
| 近半年 | -1.45% | 1595/4920 |
| 近一年 | 6.51% | 1453/4366 |
| 近两年 | 114.43% | 441/2954 |
| 近三年 | 65.99% | 364/2253 |
| 成立以来 | 102.32% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.61% 1882/4961 |
36.79% 883/5312 |
- - |
- - |
| 2025 | 51.08% 450/4813 |
-1.79% 2777/3635 |
3.24% 1086/4076 |
50.48% 305/4524 |
-0.98% 2759/4813 |
| 2024 | 14.13% 1072/3463 |
-3.97% 1592/2808 |
-6.59% 1981/3014 |
29.30% 166/3129 |
-1.60% 1766/3463 |
| 2023 | -18.86% 1831/2656 |
2.24% 1394/2280 |
-7.17% 1798/2385 |
-9.54% 1844/2515 |
-5.50% 1375/2655 |
| 2022 | -29.15% 1591/2207 |
-19.98% 1515/1919 |
6.00% 791/2016 |
-18.52% 1719/2113 |
2.53% 909/2208 |
| 2021 | 12.45% 382/1822 |
-6.93% 1047/1255 |
26.32% 73/1330 |
-6.57% 957/1466 |
2.38% 609/1822 |
| 2020 | 66.18% 91/1250 |
3.90% 103/1028 |
30.88% 46/1067 |
5.71% 898/1164 |
15.61% 197/1184 |
| 2019 | - - |
- - |
- - |
- - |
10.35% 144/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 天弘创业板ETF VS. 长安沪深300非周期A(740101) |